Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome
Authors
Keywords
Non-alcoholic fatty liver disease, Metabolic syndrome, Lipid indices, Liver fibrosis scores
Journal
Arab Journal of Gastroenterology
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-02
DOI
10.1016/j.ajg.2020.12.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
- (2018) Xia Sheng et al. HORMONE AND METABOLIC RESEARCH
- Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue
- (2018) Sofia Dias et al. International Journal of Endocrinology
- Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance
- (2017) Jinghua Song et al. GYNECOLOGICAL ENDOCRINOLOGY
- Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects
- (2017) Belqes Abdullah Mohammad Al-Tahami et al. JOURNAL OF NIPPON MEDICAL SCHOOL
- Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients
- (2017) Rashid Ali Khan et al. Therapeutics and Clinical Risk Management
- A nem alkoholos zsírmáj mint a metabolikus szindróma komponense és kauzális kapcsolatai egyéb kórképekkel
- (2017) Tamás Halmos et al. ORVOSI HETILAP
- Conicity Index and Waist-to-Hip Ratio Are Superior Obesity Indices in Predicting 10-Year Cardiovascular Risk Among Men and Women
- (2015) Nima Motamed et al. CLINICAL CARDIOLOGY
- The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease
- (2015) Daniele Pastori et al. DIGESTIVE AND LIVER DISEASE
- Nonalcoholic fatty liver disease and statins
- (2015) Konstantinos Tziomalos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
- (2015) N. M. Aldekhail et al. Obesity Reviews
- Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2015) Yoshihisa Takahashi WORLD JOURNAL OF GASTROENTEROLOGY
- Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index
- (2015) Qing Pang WORLD JOURNAL OF GASTROENTEROLOGY
- Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance
- (2014) Tingting Du et al. Cardiovascular Diabetology
- New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
- (2014) Amirhossein Sahebkar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults
- (2012) Ryuichi Kawamoto et al. Cardiovascular Diabetology
- The role of lipid droplets in metabolic disease in rodents and humans
- (2011) Andrew S. Greenberg et al. JOURNAL OF CLINICAL INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation